Jim Sahn
Co-Founder NuvoNuro
Seminars
Thursday 24th September 2026
Advancing TMEM97 Modulation to Deliver Safer & More Selective Small Molecule Therapies for Neuropathic Pain
3:30 pm
- NuvoNuro is developing small molecule modulators of TMEM97 for the treatment of neuropathic pain
- Proof of principle has been established using human dorsal root ganglion neurons and rodent pain models
- Objectives for medicinal chemistry optimization include reducing hERG binding, improving physicochemical properties and enhancing specificity for TMEM97
